The global colorectal cancer therapeutics market is characterised by a competitive landscape with numerous players striving to develop and deliver effective treatments for colorectal cancer. The market features a mix of multinational pharmaceutical companies, biotechnology firms, and research institutions actively engaged in the research, development, and commercialization of colorectal cancer therapeutics. Competition in the market revolves around factors such as the efficacy of therapies, safety profiles, and the ability to target specific molecular pathways involved in colorectal cancer progression. Market players invest significantly in research and development activities to discover novel treatment approaches, develop innovative therapies, and conduct clinical trials to assess their efficacy. Strategic partnerships and collaborations are common in the market as companies seek to leverage each other's strengths and resources. Collaborations between pharmaceutical companies, research institutions, and academic centres help in sharing knowledge, accessing specialised expertise, and expediting the development of new therapeutic interventions. 'Roche Holding AG - Switzerland', 'Pfizer Inc. - US', 'Merck & Co., Inc. - US', 'Bristol-Myers Squibb Company - US', 'AstraZeneca PLC - UK', 'Novartis AG - Switzerland', 'Eli Lilly and Company - US', 'Sanofi S.A. - France', 'Johnson & Johnson - US', 'AbbVie Inc. - US', 'Bayer AG - Germany', 'Takeda Pharmaceutical Company Limited - Japan', 'Amgen Inc. - US', 'Gilead Sciences, Inc. - US', 'Celgene Corporation - US', 'Ipsen - France', 'Daiichi Sankyo Company, Limited - Japan', 'Exelixis, Inc. - US', 'Seattle Genetics, Inc. - US', 'Taiho Pharmaceutical Co., Ltd. - Japan'